Trial Profile
A Real-world retrospective observational patient registry for Oritavancin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2019
Price :
$35
*
At a glance
- Drugs Oritavancin (Primary)
- Indications Gram-positive infections; Skin and soft tissue infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHROME
- 12 Oct 2018 New trial record
- 05 Oct 2018 According to a Melinta Therapeutics media release, data from this trial was published in the journal Open Forum Infectious Diseases (June 2018).